Obesity is common in inflammatory arthritis, with an estimated 60-70% of people with rheumatoid arthritis and 70-80% of people with psoriatic arthritis also living with overweight or obesity. But does obesity affect disease activity and outcomes in inflammatory arthritis?
All News
Article
Article
Obesity is associated with poorer physical function and treatment response in rheumatoid arthritis (RA). The ACR guideline on exercise, rehabilitation and diet supports discussing healthy body weight as part of wider RA care. But what happens to patients’ symptoms when they lose weight after starting GLP-1-based treatment?
Article
ACR Convergence was off to a big start with the year in review, posters and plenary sessions. Here are a few of my favorite presentations from todays Plenary I session at ACR Convergence.
Adela Castro
Tweet
Prevalence of SpA features in IBD:
-Meta-analysis of 81 studies (>110,000 IBD patients, 23 countries): pooled prevalence of SpA features in IBD was 13.4% for peripheral arthritis, 8.9% for sacroiliitis and 3.5% for AS.
-Twelve studies contributed incidence data: the largest https://t.co/77hqhWaPi9
Richard Conway
Tweet
Natalucci et al. Case series combination JAKi and bDMARD in multi-refractory RA (6 patients) (and 1 PsA, 1 SpA) @RheumNow #ACR26 Abstr#1403 https://t.co/vGrwzbd5y1
Brian Jaros, MD
Tweet
Upadacitinib beats out Deucravacitinib in PsA
SELECT-PsA pt matched to POETYK-PsA pt
Week 12 UPA wins vs. week 16 DEU at:
- ACR 20
- ACR 50
- ACR 70
- MDA
Surprisingly similar safety signals but short-term timepoint
#ACR26 @RheumNow #Abst1309 https://t.co/Z3CQ7DcmZj
Antoni Chan MD (Prof)
Tweet
US claims data: 21.7% of bimekizumab treated PsA patients and 21.0% with axSpA were also on a GLP1 or GLP1/GIP agonist. Key finding: concomitant use was common, and the agonist was most often started before bimekizumab. @rheumnow #ACR26 Abstract#1304
Antoni Chan MD (Prof)
Tweet
Bimekizumab in overweight and obese PsA, pooled to 3 years: ACR50 41.0% with BMI 35 or more, 45.9% with BMI 30 or more, and 56.8% with BMI 27 to 30 plus comorbidity. Key finding: efficacy was sustained across BMI groups, with safety consistent with the overall population.
Adela Castro
Tweet
Double targeted therapy in refractory SpA/PsA
Spanish multicentre cohort of 76 refractory SpA/PsA patients on double targeted therapy (DTT), median follow-up 15 months.
-Most common: TNFi + IL-12/23i (30%), then TNFi + IL-17i (17%)
-Mean ASDAS fell from 3.7 to about 2.0 by 6
Antoni Chan MD (Prof)
Tweet
TriNetX, 7,083 matched PsA pairs: GLP1 RA prescription was associated with lower 3 year risk of joint effusion (RR 0.77), joint pain (RR 0.83) and steroid injection (RR 0.91). Key finding: GLP1 RA use was associated with improved joint outcomes; coded psoriasis was higher.
Brian Jaros, MD
Tweet
The hottest treatment for TAK is... exercise?
Online survey to TAK pt assessed exercise
- 74% were rec'd exercise by MDs
- 73% reported exercising
Of 87% w/ arm involvement -> 35% improved sx w/ exercise
Comparable to improvement attributed to meds!
@Rheumnow #ACR26 #Abst1131
With weight loss: ↓ leptin, ↑ appetite, ↓ energy expenditure
But leptin therapy ineffective for weight loss
Leptin --> pro-inflammatory --> higher in PsA --> correlate with disease acitivty and duration
@RheumNow #ACR26 https://t.co/2gUjaMGzxM
Why does obesity matter in RD?
↑ risk of developing common arthritides
↑ disease activity or severity
↓ response to common inflammatory arthritis therapies
Session: Fat, Fate, and Flares @RheumNow #ACR26 https://t.co/s4i7DokEkr
Antoni Chan MD (Prof)
Tweet
INSPIRE 2, tildrakizumab 100 mg every 12 weeks in TNFi naive PsA (n=296): at week 24, ACR20 34.8% vs 22.7%, ACR50 22.3% vs 14.4% and PASI 75 31.6% vs 11.1% with placebo. Key finding: the primary endpoint was met, responses improved to week 52 (ACR20 about 62%), and no new safety
Antoni Chan MD (Prof)
Tweet
Izokibep, a novel IL17A inhibitor, phase 2b/3 in PsA (n=343): week 16 ACR50 was 41% to 46% vs 18% with placebo in TNFi naive patients, and 33% to 37% vs 7% after prior TNFi. Key finding: responses exceeded placebo across all subgroups studied and were maintained or improved to
Antoni Chan MD (Prof)
Tweet
Bimekizumab over 3 years in axSpA (n=586) and PsA (n=1,112) with high systemic inflammation: hsCRP and NLR fell in every subgroup. Key finding: no adjudicated MACE occurred in axSpA, MACE incidence in PsA was low (EAIR 0.3/100 PY), and other cardiometabolic markers were stable.
Proposal for clinical remission (CR) and low disease activity (LDA) from VALOR data (brep vs plbo in dermato)
LDA: PtGA-VAS < 4, PhGA-VAS < 4, and OCS dose ≤ 5 mg/d
CR propposal: PtGA-VAS ≤ 1, PhGA-VAS ≤ 1, and OCS ≤ 2.5 mg/d prednisone-equivalent.
Sounds reasonable? https://t.co/jZAJ1IjSTO
Brian Jaros, MD
Tweet
New IL-17 inhibitor on the block?
Post-hoc analysis of Izokibep (small, selective IL-17A inhibitor) shows significant improvement over placebo in high-threshold outcomes including ACR70 response by week 16
#Abst0360 @RheumNow #ACR26 https://t.co/5tXgxBXK3C
Audrey Gibson
Tweet
Mehta et al. (Toronto PsA GLP-1 cohort): Could GLP-1 agents influence PsA symptoms beyond weight loss? The Mehta cohort raises that possibility. Its observational design and limited follow-up samples call for further investigation. @rheumnow #ACR2026 Abstract#0373 https://t.co/sgk3yB5PK5
Akhil Sood MD, MS
Tweet
What is effect of GLP-1 on disease activity in PsA?
Abstract 0373: compared to non-GLP1 use, GLP-1 use associated w/
- decrease in disease activity (cDAPSA β −0.45, DAPSAβ −0.63) and pain (β −0.13)
- association persisted after adjusting change in BMI
@RheumNow #ACR26 https://t.co/f7tSI2zvad
